Advanced Viral Research CP (ADVR) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Advanced Viral Research CP (ADVR)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: .com who wrote (1846)	12/10/1996 7:55:00 PM
From: DAN LITTLE	of 2281

Here is a more generalized version of the results. I picked this up from AOL news release. NEW YORK, Dec 10 (Reuter) - Advanced Viral Research Corp said Tuesday that preliminary results of a clinical trial of its drug Reticulose in patients with AIDS were "encouraging" and showed no toxicity or side effects. Advanced Viral said in a release that its drug Reticulose is a non-toxic peptide nucleic acid preparation that in the past was used to treat a number of viral infections. The company said that in view of "encouraging preliminary results" of the clinical study in AIDS patients and the absence of any toxic side effects, it is eager to move forward to the next stage of the trial. 10:28 12-10-96 Advanced Viral said that the trial took 43 patients who had never received treatment with HIV anti-retroviral therapy. Twenty-one of them received Reticulose and twenty-two received a placebo. The results of the trial included a 37 percent increase in the mean CD4 positive T-cell lymphocytes counts in patients receiving the drug, while there was a seven percent decrease in the control group that received placebo. The company reported a 21 percent average decrease in HIV viral load in the Reticulose-treated patients, while there was a 33 percent increase in HIV viral load in the control group. 14:03 12-10-96 Clinically, the company said that 72 percent of patients given Reticulose maintained or increased body weight, while only 30 percent of the placebo-treated patients maintained or increased body weight. The clinical trial was conducted at the Queen Elizabeth Hospital at the University of the West Indies School of Medicine in Barbados, Advanced Viral said. 14:04 12-10-96 I know its the same report, just a little different. DAN

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next